期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 182, 期 5, 页码 693-700出版社
WILEY
DOI: 10.1111/bjh.15453
关键词
chronic myeloid leukaemia; uncommon BCR-ABL1 transcripts; tyrosine kinase inhibitors; cytogenetic and molecular response; outcome
类别
资金
- Natural Science Foundation of China [81770161, 81570130]
To explore the type, prevalence and outcomes in chronic myeloid leukaemia (CML) patients with uncommon BCR-ABL1 transcripts in the era of tyrosine kinase inhibitors (TKIs), uncommon BCR-ABL1 transcripts were screened in 4750 patients by multiplex polymerase chain reaction (PCR), and type-specific real-time quantitative PCR was regularly performed for molecular monitoring. A total of 19 uncommon transcripts, including e1a2, e1a3, e6a2, e8a2, e12a2, unusual e13a2, e13a3, unusual e14a2, e14a3 and e19a2 were identified in 83 (1 7%) patients. The three most frequent types were e19a2, e13a3/e14a3 and e1a2. Compared with the 571 newly diagnosed CML patients in chronic phase with common e13a2/e14a2 transcripts receiving frontline imatinib therapy, patients with the e19a2 (n=16) and e1a2 (n=11) transcripts had significantly reduced probabilities of 1-year complete cytogenetic response (CCyR, P=0 0004 and 0 016) and major molecular response (MMR, P=0 0018 and 0 0035), and patients with the e13a3/e14a3 transcript (n=10) had significantly increased probabilities of 1-year CCyR (P=0 0072) and MMR (P=0 0073). Patients with the e19a2 transcript had low probabilities of 2-year event-free survival (EFS, P=0 0004) and progression-free survival (P=0 0067), and patients with the e1a2 transcript had low probability of 2-year EFS (P<0 0001). Therefore, uncommon BCR-ABL1 fusion transcripts are rare and diverse in patients with CML and may be relevant for TKI therapy outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据